Zobrazeno 1 - 10
of 123
pro vyhledávání: '"Michael D Huband"'
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 27, Iss , Pp 337-351 (2021)
ABSTRACT: Objectives: Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standa
Externí odkaz:
https://doaj.org/article/b6b0abce50e94fef96675a379b737ba2
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 26, Iss , Pp 117-127 (2021)
ABSTRACT: Objectives: : Manogepix, the active moiety of the prodrug fosmanogepix, is a novel antifungal with activity against major fungal pathogens including Candida (except Candida krusei), Aspergillus and difficult-to-treat/rare moulds. We tested
Externí odkaz:
https://doaj.org/article/efc20a7303c74cdcbe326752c5355ae6
Autor:
David B. Huang, Leonard R. Duncan, Yahse K. Edah, Paul R. Rhomberg, Robert K. Flamm, Michael D. Huband
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 25, Iss , Pp 14-17 (2021)
Objectives: This study examined the in vitro activity of iclaprim and comparators against 40 Listeria monocytogenes clinical isolates mostly (95%) from patients with bloodstream infection (BSI) from the USA, Australia/New Zealand, Latin America and E
Externí odkaz:
https://doaj.org/article/35ba935f16e04570a03426ec828258a0
Autor:
Cecilia G. Carvalhaes, Paul R. Rhomberg, Michael D. Huband, Michael A. Pfaller, Mariana Castanheira
Publikováno v:
Journal of Fungi, Vol 9, Iss 2, p 241 (2023)
Isavuconazole is the only US FDA-approved antifungal for treating invasive mucormycosis. We evaluated isavuconazole activity against a global collection of Mucorales isolates. Fifty-two isolates were collected during 2017–2020 from hospitals locate
Externí odkaz:
https://doaj.org/article/0ce1fa506faf4f1692048a83fe004569
Autor:
Joshua M Maher, Michael D Huband, Christopher G Blankers, Sailaja Puttagunta, Steven I Aronin, Mariana Castanheira
Publikováno v:
Journal of Antimicrobial Chemotherapy. 78:1406-1414
Objectives Physicians must leverage several factors when making antibiotic therapy decisions, including route of administration and duration of therapy. Oral administration provides several potential advantages including increased accessibility, prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32557c75883eea7e7cdcfd1d7813a1ae
https://doi.org/10.1093/jac/dkad099
https://doi.org/10.1093/jac/dkad099
Autor:
Helio S. Sader, Cecilia G. Carvalhaes, Michael D. Huband, Rodrigo E. Mendes, Mariana Castanheira
Publikováno v:
European Journal of Clinical Microbiology & Infectious Diseases. 42:453-459
We evaluated the in vitro activity of ceftibuten-avibactam against Enterobacterales causing urinary tract infection (UTI). A total of 3216 isolates (1/patient) were consecutively collected from patients with UTI in 72 hospitals from 25 countries in 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff5549ac47500584d28dcdbefd628629
https://doi.org/10.1007/s10096-023-04562-4
https://doi.org/10.1007/s10096-023-04562-4
Autor:
Alina Nussbaumer-Pröll, Sabine Eberl, Adam Belley, Philipp Knechtle, Michael D. Huband, Holly K. Huynh, Markus Zeitlinger
Publikováno v:
The Journal of Antibiotics. 76:183-189
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ace60ac73ea5217d3eb442c1bbee47d
https://doi.org/10.1038/s41429-022-00592-w
https://doi.org/10.1038/s41429-022-00592-w
Autor:
Sujata M. Bhavnani, Jeffrey P. Hammel, Elizabeth A. Lakota, Michael Trang, Justin C. Bader, Catharine C. Bulik, Brian D. VanScoy, Christopher M. Rubino, Michael D. Huband, Lawrence Friedrich, Judith N. Steenbergen, Paul G. Ambrose
Publikováno v:
Antimicrobial Agents and Chemotherapy. 67
Omadacycline, a novel aminomethylcycline with in vitro activity against Gram-positive and -negative organisms, including Streptococcus pneumoniae and Haemophilus influenzae , is approved in the United States to treat patients with community-acquired
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f512cb865e5b1e50a1aff17b6dce35ce
https://doi.org/10.1128/aac.02213-21
https://doi.org/10.1128/aac.02213-21
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 27, Iss, Pp 337-351 (2021)
Objectives: Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Methods: Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Instit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c991d47b45484012d611ae7b33567e50
http://www.sciencedirect.com/science/article/pii/S2213716521002356
http://www.sciencedirect.com/science/article/pii/S2213716521002356
Publikováno v:
Open Forum Infectious Diseases. 9
Background Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibacterial approved in the US for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections. DLX is indicated to treat CA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a969275ea097e6c2a49c93201fd58915
https://doi.org/10.1093/ofid/ofac492.1796
https://doi.org/10.1093/ofid/ofac492.1796